Animal health company Zoetis Inc. (ZTS) is closing out 2025 with a wave of regulatory progress that could reshape its product portfolio across companion animal and livestock care. Recent approvals and positive opinions from global health authorities indicate the company's continued commitment to long-acting monoclonal antibody therapies for osteoarthritis pain, an area of growing clinical and commercial significance.
With updated financial guidance and multiple launches expected in 2026, Zoetis is positioning itself for sustained performance in the year ahead.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com